// App-Quantinova.ai

: Pre-Transplant NPM1 Mutant Transcript Level Is Highly Predictive of Outcome after Allograft and Thresholds Are Dependent on FLT3 ITD Status

Researchers

Presenter

  • Richard Dillon

Principal Investigators

  • Robert K. Hills

  • Sylvie D Freeman

  • Nicola Potter

  • Adam Ivey

  • Jelena Jovanovic

  • Anju Kanda

  • Manohursingh Runglall

  • Nicola Foot

  • Laura Upton

  • Asim Khwaja

  • Jamie Cavenagh

  • Ruth Spearing

  • Alan K. Burnett

  • Nigel H. Russell

  • David Grimwade

Medical Centers

  • Kings College London, London, United Kingdom

  • Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University, Cardiff, United Kingdom

  • Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom

  • Department of Anatomical Pathology, Alfred Hospital, Melbourne, Australia

  • Molecular Oncology Diagnostics Unit, ViaPath LLP, London, United Kingdom

  • Centre for Trials Research, Cardiff University, Cardiff, United Kingdom

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Department of Histopathology, St. Bartholomews Hospital, London, United Kingdom

  • Canterbury District Health Board, Christchurch, New Zealand

  • Blackwaterfoot, Cardiff, United Kingdom

  • Nottingham City Hospital, Nottingham, United Kingdom

Locations

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute promyelocytic leukemia

Biomarkers

  • Nucleophosmin 1

  • Fms related tyrosine kinase 3

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved